- Home
- NVCT vs CRMD Comparison
NVCT vs CRMD Comparison
Compare NVCT & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVCT | CRMD |
|---|---|---|
| Founded | 2020 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 672.1M | 590.7M |
| IPO Year | 2021 | 2009 |
Fundamental Metrics
Financial Performance| Metric | NVCT | CRMD |
|---|---|---|
| Price | $20.07 | $5.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $35.40 | $14.83 |
| AVG Volume (30 Days) | 164.7K | ★ 1.7M |
| Earning Date | 11-04-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 780.00 |
| EPS | N/A | ★ 0.72 |
| Revenue | N/A | ★ $311,709,000.00 |
| Revenue This Year | N/A | $7.98 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $7.86 |
| Revenue Growth | N/A | ★ 617.03 |
| 52 Week Low | $5.77 | $5.30 |
| 52 Week High | $29.28 | $13.02 |
Technical Indicators
Market Signals| Indicator | NVCT | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 52.92 | 26.61 |
| Support Level | $19.78 | N/A |
| Resistance Level | $22.56 | $8.76 |
| Average True Range (ATR) | 1.59 | 0.49 |
| MACD | 0.10 | -0.26 |
| Stochastic Oscillator | 65.80 | 5.68 |
Price Performance
Historical ComparisonAbout NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.